In conclusion, developing GCGR agonists, particularly unimolecular dual and multi‐agonists, represents a promising avenue for addressing obesity, diabetes and metabolic disorders. This evidence concerns the gene GCGR and obesity due to melanocortin 4 receptor deficiency.